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    The interest of皿’any urologists in chemotherapy of carcinoma of the prostate has recently ariserl
in treatment gf intractable cases to anti－androgen therapy． Several clinical trials in broadly organized
pr（？jg¢t．¢耳卑『，． sμψ． as NPGP．加．口．S．A．， are now progressing， but they have not produced’definit圭ve
c6nciUsiOns yet． We herein report the experimental results on effectiveness of several non－hormonal
anti－tumor agentstested in nude mice with tumors resulting from inocculation of cultured EB 33 cells
which had been established from human prostatic cancer tissue． Three representative chemothe－
rapeutics such as 5－fluorouracil （5－FU） or Futrafu1， a masked compound of 5－FU， cyclophosphamide
（GPM）and v量ncristine（VCR）were principa五candidates for the experiment， and cis－diammined量chlo－
ride platinum （CDDP） and Estracyt were also tested． The effect of these drugs was evaluated through
statistical analysis of the tumor growth curve compared to that of the control group． The drugs were
i．，．sually injp．．cted intr－aper，：tonea．11y for consecutive 14 days except for VCR， 7 times per 3 days， and
CDDP， for consecutive 5 days． The results obtained are as follows．
    1） 5－FU， 20 mg／kg， did not show tumor reduction， while 60 mg／kg of FT did a tendency of growth
inhibition compared to controls with less decrease of body weight than 5－FU．
    2） CPM and VCR brought a significant tumor reduction compared to controls at the doses of
10 mg and 0．45 mg per kg， respectively． ln VCR group， however， 3 of 6 animals suffereq from disten－
sion of intestine during experimental period， while only minimal loss of body weight occurred in CPM
group．
    3） A combination of 2 of 3， and all of the 3 above mentioned ’agents ・were also examined if there
was a synergic effect among them． CPM plus VGR showed an additive effect， but neither multiplied
nor additive effect was recognized in other combinations．
    4） Estracyt， 20 mg／kg， did not show any significant change in tumor growth， although rather
marked decrease of body weight occurred at this do．se．
    5） CDDP showed apparent inhibition of tumor growth， although shortage of numbers of tested
animals prevented from statistical analysis．
    It is concluded through the experimental result’ that CPM and／or VCR， and CDDP seem to be
effective chemotherapeutics for carcinoma of the prostate． The result has alrnost corresponded to
994 泌尿紀要25巻 10号 1979年
those in clinical reports up to date． This experimental mode｝ will be a usefu1 tool in further study
for carcinoma of the prostate， since EB 33 ce｝ls well preserve original characteristics as human
prostatic epithclial cel正s．
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Fig．3． Gis－diamminedichloride platinum
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単剤としての効果検討には5－FU 20皿9／kg， FT 60 mg










































































































 Controt growth curve
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 10 20 30 40                Days
対照群ヌードマウス20匹のEB 33腫瘍
の増殖曲線．
 1 3 5 7 9 11 13 1’S 1’1 1’9 il                   Days
Fig．5．5・FU 20 mg／kg／day連日14日間投与に
    よる4匹のヌードマウスEB 33腫瘍の
    体積の変動（平均値±SE）および平均体













































































































Table 4． EB 33腫瘍担癌ヌードマウス（6匹）に対
     するcyclophosplramide（CPM）10 mg／kg











    f 3 5 7 9 11 13 15 IT 19 21                      Days
Fig．6． FT 60 mg／kg／day連日14日間投与による13
    匹のヌードマウスEB 33腫瘍の増殖曲線
    第9日目に対照群にくらべ縮小の傾向がみら





































































＊ P〈 O． 10
緋P〈0．05
（一）は縮小を示す。
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   1 3 5 7 9 11 13 1’5 O i9 2’1                     Days
Fig．7． CPM l O mg／kg／day 14日間連続投与による
    6匹のヌ」ドマウスEB 33腫瘍の体積の変
    動（平均値±SE）および平均体重の増減．
Table 5． EB 33腫瘍類癌ヌードマウス（6匹）に対
     するViner量stine（VCR）0．45 mg／kg 3日




   control
戟｡change of BW（9m》f






                   Days
Fig．8． VCR O．45 rng／kg／day 3日毎7回投与によ
    る6匹のヌードマウスEB 33腫瘍の体積の
    変動（平均値±SE）および平均体重の増減．
































































































FT 50mg／kg／day       IPCPM 5㎎ノkg／day，
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13 5 7 9 11 13 15 17 19 21                   Days
Fig．9． FT－20750 mg／kg， CPA 5皿g／kg併用によ
    るヌードマウス5匹のEB 33腫蕩の体積の







          （  n＝4mean±SE）
FT 30nglkg／dey， VCR O．225aigtkgr3 deys． IP
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Fig．11， CPM 5 mg／kg， VCR O．225 mg／kg連目14
     日戸投与による4匹のヌードマウスEB 33
    腫瘍平均体積の変動（平均値±SE）および
    平均体重減小．
O．OOI  13 5 7 9 11 13 15 17 19 21                      Days
Fig・10・FT 30 mg／kg連日14日間， VGR O．225 mg／
    kg 3日毎7回投与によるヌードマウス4匹
    のEB 33腫瘍の体積の変動（平均値±SE）











1／3に減量した．すなわちFT 30 mg／kg， CPM 3．3





















          （ n＝6mean±SE）
  Effect of CDDP to EB 33 tumor
voluse． cm
10．0










  1 3 5 7 9 11 13 15 17 19 21                     Days
Fig．12． FT 30 mg／kg， CPM 3・3mg／kg連日14日
    間，VGR O・15mg／kg 3日毎7回投与．
     3剤併用による6匹のヌードマウスEB 33
    腫蕩の体積の変動（平均値±SE）および平
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7 9 11 13 T5 17 T9 2’P i3             Days
Fig・14・CDDP 3 mg／kg／day 5日間連続投与による
    ヌードマウス2匹および対照群4匹の腫瘍
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1 3 5 7 9 11 13 15 17 19 21
Days
Fig．13． Estracyt 20 mg／kg連日14日間投与による
     6匹の．ヌードマウスEB 33腫瘍の体積の
    変動（平均値±SE）および平均体重減少．
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